TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mandibular elongation in length (Co‐Gn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower incisor proclination (IMPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal effects (Co‐Gn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of AA/multiplex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative C-spine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fatal pump failure events
Endpoint domain: Mortality/survival
Primary endpoint: sdLDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AGIS asymmetry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean deviation (MD) asymmetry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progressive motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction in physical disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Oxidation (COX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Oxidation (FOX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severe erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cure rate of lacrimal passage obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to CDC group IV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in CD4+ cell counts to below 350 per cubic millimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pre-sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anatomic outcomes for the anterior vagina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of binges per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful tube placements at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end-diastolic diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe IVH diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: postprandial lipid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postchallenge glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent days of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycated hemoglobin (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% improvement in pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent complications at 12-month follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in chief symptoms and physical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good or excellent function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Good to excellent results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom scores (anorexia, weakness, abdominal distension, constipation, nausea, vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of motilin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: perceived tinnitus loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for anticoagulation treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prescription of warfarin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of vibegron treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance in a Go/No-Go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in signs and symptoms of blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: tooth color enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse of tooth shade
Endpoint domain: Adverse events/effects
Primary endpoint: vasodilation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exposure to N2O and sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of noticing a 'smell of gas'
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of general discomfort, nausea, and headache
Endpoint domain: Adverse events/effects
Primary endpoint: Remission rate (HAM-D score < 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak methemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to 50% wound volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma morphine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of plasma morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak plasma morphine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders at week 12 on CANTAB RVIP A' or HVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF‐I concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Th(1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in TSTh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trunk Forward Lean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFL (Thoracic Flexion Load)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived involvement in medical decision making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LBF (Laser Doppler Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gastric half-emptying time (T50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: QALY score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall stress decrease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Agreement between observers' decisions and FFR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in performance of practical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Active flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overnight hypoglycemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean glucose level from 10 pm to 6 am
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repigmentation of vitiligo patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Retention rates at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Heart Disease (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Cardiovascular Disease (CVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biopsy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of vocal cord sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrin monomer level
Endpoint domain: Mortality/survival
Primary endpoint: Intraobserver repeatability (ICC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak tissue concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight gain after eight weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simplified strong ion difference (SID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global gene expression in the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At least one adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: development of erythroid hypoplasia
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rate of suppurative chronic otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of GONAL-f injector
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total handling errors
Endpoint domain: Adverse events/effects
Primary endpoint: vitality rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Loco-Regional Failure-Free Survival (LFS)
Endpoint domain: Mortality/survival
Primary endpoint: Minimum local analgesic volume (MLAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum local analgesic dose (MLAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of IOP readings within +/- 2 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure (IOP) control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall nasal symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sneezing improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for buffered solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Healing rate of simple bone cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSH levels during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fraction of time above the suggested threshold for osteoporosis prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition and working memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CES-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface costs per at-risk patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Child's participation challenges
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of long-term use of the platform
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of clinically relevant O(2) desaturation (S(p)O(2)≤90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptomatic medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific nasal challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in numeric rating scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in Functional Pain Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of fussing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of colicky crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of fussing, crying and colicky crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron absorption from meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sexual violence from clients
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety state of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts for iv cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cardiac symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MHC IIX composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MHC I composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: toe analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: finger analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of subjective side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of incident epilepsy after dementia
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory domain score on the Cystic Fibrosis Questionnaire‐Revised
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Facial nerve function assessment consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vegetable preference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude (AT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IBS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVEF (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients without therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with HIV RNA 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall and performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean incorrect response rate in auditory working memory tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in practical skills of midwives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term patient outcome
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction rate with synthetic mesh for POP surgery correction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Commencing employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Delivered or ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: self-reported functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Retention in treatment for opioid dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continued use of illicit opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose excursion during an oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in depression, anxiety, and daily stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protection against methacholine-induced bronchospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchodilatation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sufficient overall vessel attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full immunization by the age of 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of remission, partial response, and complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate V100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Computation time for treatment plans
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: amount taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative time to readiness for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-efficacy for modifying diet
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements on MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean increases in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patients gained ≥7% body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak filling rate in end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT dispersion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of WHO grade III-IV cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) for amprenavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for ketoconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall performance score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median percent reduction in standardized seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Agreement between parent and teacher ratings of ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for stage 3 and 4 ulcers to reach stage 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Wound healing outcomes
Primary endpoint: Propofol requirements for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alfentanil requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parietal box damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: tool collisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inter-rater reliability of the sitting active lag test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater reliability of the prone passive lag test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete disappearance of varicose veins and telangiectases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative restoration survival after 2 years
Endpoint domain: Mortality/survival
Primary endpoint: ECMO/death rates
Endpoint domain: Mortality/survival
Primary endpoint: progression of respiratory failure to OI >30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain scores 2 weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes